📗 Cite This Artifact
cGAS-STING Cytosolic DNA Sensing Pathway in Neurodegeneration
cGAS-STING Cytosolic DNA Sensing in Neurodegeneration
Overview
The cGAS-STING (cyclic GMP-AMP synthase — Stimulator of Interferon Genes) pathway is the primary cytosolic DNA sensing mechanism of the innate immune system. It detects aberrant DNA in the cytoplasm — derived from genomic instability, mitochondrial DNA (mtDNA) release, nuclear envelope breakdown, or micronuclei — and triggers a type I interferon (IFN) response, inflammatory cytokine production, and cell death via pyroptosis and necroptosis[@schoggen2022]. Chronic cGAS-STING activation is increasingly recognized as a driver of neuroinflammation and neurodegeneration across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[@paul2023].
The pathway operates through sequential activation: cytosolic dsDNA binds cGAS → conformational change → cGAMP synthesis → STING trafficking from the endoplasmic reticulum to the Golgi → TBK1/IKKε phosphorylate IRF3 → type I IFN gene transcription[@schoggen2022]. Chronic STING activation drives microglial activation, sustained neuroinflammation, and progressive neuronal loss[@liu2024].
Cross-Disease Comparison Matrix
...
cGAS-STING Cytosolic DNA Sensing in Neurodegeneration
Overview
The cGAS-STING (cyclic GMP-AMP synthase — Stimulator of Interferon Genes) pathway is the primary cytosolic DNA sensing mechanism of the innate immune system. It detects aberrant DNA in the cytoplasm — derived from genomic instability, mitochondrial DNA (mtDNA) release, nuclear envelope breakdown, or micronuclei — and triggers a type I interferon (IFN) response, inflammatory cytokine production, and cell death via pyroptosis and necroptosis[@schoggen2022]. Chronic cGAS-STING activation is increasingly recognized as a driver of neuroinflammation and neurodegeneration across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[@paul2023].
The pathway operates through sequential activation: cytosolic dsDNA binds cGAS → conformational change → cGAMP synthesis → STING trafficking from the endoplasmic reticulum to the Golgi → TBK1/IKKε phosphorylate IRF3 → type I IFN gene transcription[@schoggen2022]. Chronic STING activation drives microglial activation, sustained neuroinflammation, and progressive neuronal loss[@liu2024].
Cross-Disease Comparison Matrix
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|:------------------:|:------------------:|:---:|:---:|:--------------------:|
| Primary DNA source | mtDNA, nuclear blebs | mtDNA, α-syn–damaged nuclei | mtDNA, TDP-43 nuclear loss | GRN/C9orf72 nuclear envelope | mHTT-disrupted nuclei |
| cGAS activation level | High (early onset) | Moderate-High | High | High (GRN-FTD) | Moderate-High |
| STING expression | Elevated in microglia/neurons | Elevated in substantia nigra | Elevated in motor neurons | Elevated in frontal cortex | Elevated in striatum |
| Type I IFN response | Strong, chronic | Moderate, focal | Strong, widespread | Strong | Moderate |
| Inflammasome cross-talk | NLRP3 + cGAS-STING | NLRP3-driven | AIM2 + cGAS-STING | NLRP3 + cGAS-STING | cGAS-STING dominant |
| Cell death mechanism | Pyroptosis, necroptosis | Pyroptosis | Pyroptosis, necroptosis | Apoptosis, pyroptosis | Pyroptosis |
| Key experimental evidence | Mouse models, patient CSF[@liu2024] | MPTP/toxin models, patient tissue[@ma2024] | SOD1/TDP-43 models, patient tissue[@li2023] | GRN KO mice, patient tissue[@fang2023] | BAC-HD mice, patient tissue[@wang2024] |
| BBB penetration relevance | High (systemic DNA release) | Moderate | Moderate | Moderate | Low |
| Imaging/CSF biomarker | CSF cGAMP, ISG15/MX1 | CSF IFN-γ, p-TBK1 | p-STING in spinal cord | STING in CSF/frontal cortex | p-IRF3 in striatum |
| Therapeutic tractability | High (H-151, C-176 effective) | High (STING antagonists work) | Moderate (delivery challenge) | High (GRN-FTD strong target) | Moderate |
Shared Mechanisms
Cytosolic DNA Accumulation
All five diseases exhibit cytosolic DNA accumulation as a primary trigger of cGAS-STING activation[@xia2022]. Sources include:
- Mitochondrial DNA release: mtDNA escapes damaged mitochondria into cytosol following oxidative stress, membrane permeabilization, or mitochondrial permeability transition. Particularly prominent in AD (Aβ-induced), PD (α-syn–induced), and ALS (SOD1/TDP-43-mediated)[@chen2022].
- Nuclear envelope dysfunction: Loss of nuclear integrity from tau pathology (AD), α-synuclein (PD), TDP-43 (ALS/FTD), or mHTT (HD) allows nuclear DNA to escape into the cytoplasm[@fang2023].
- Micronuclei formation: Chromosomal instability creates micronuclei whose envelopes rupture, releasing dsDNA that potently activates cGAS. Elevated in ALS and FTD[@xia2022].
- Genomic instability: Impaired DNA repair (known in HD, ALS) causes DNA damage accumulation, generating cytosolic DNA fragments[@wang2024].
Microglial cGAS-STING Activation
Microglia are the primary responders to cGAS-STING activation in the CNS. Chronic STING activation transforms microglia into a hyper-inflammatory state characterized by:
- Sustained type I IFN signature (ISG15, MX1, OAS1 upregulation)[@ahn2021]
- Pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β)
- Impaired phagocytic clearance of protein aggregates (Aβ, α-syn, TDP-43)
- Synapse elimination and dendritic spine loss[@zhang2022]
In AD, microglial cGAS-STING activation by Aβ-induced mtDNA release drives a type I IFN response that impairs Aβ clearance and accelerates tau pathology[@liu2024].
Neuroinflammation and Cell Death
cGAS-STING signaling drives neuroinflammation through two major routes:
Cell death via pyroptosis and necroptosis is a terminal consequence of cGAS-STING hyperactivation, contributing to progressive neuronal loss in all five diseases[@paul2023].
Disease-Specific Mechanisms
Alzheimer's Disease
In AD, amyloid-beta deposition directly damages mitochondria in neurons and glia, causing mtDNA release into the cytosol[@ahn2021]. Aβ also disrupts the nuclear envelope, releasing nuclear DNA fragments. Both sources activate cGAS-STING, establishing a chronic type I IFN response that:
- Impairs microglial Aβ phagocytosis and clearance
- Promotes tau hyperphosphorylation through IFN-α/β signaling
- Drives neuroinflammation that correlates with cognitive decline severity[@liu2024]
STING inhibition in 5xFAD and APP/PS1 mouse models reduces neuroinflammation markers, improves synaptic integrity, and rescues cognitive performance[@liu2024]. CSF cGAMP and ISG15 levels are elevated in AD patients, supporting biomarker utility.
Parkinson's Disease
In PD, alpha-synuclein aggregation and the associated mitochondrial dysfunction and oxidative stress cause mtDNA release into the cytosol of dopaminergic neurons[@schoggen2022]. The substantia nigra pars compacta is particularly vulnerable due to its high metabolic rate, elevated iron content, and proximity to systemic immune cells. STING activation in PD:
- Drives neuroinflammation in the substantia nigra and basal ganglia
- Contributes to dopaminergic neuron loss
- May facilitate α-synuclein pathology propagation through inflammatory signaling[@ma2024]
STING antagonists (H-151, C-176) protect dopaminergic neurons in MPTP and 6-OHDA models, and reduce α-synuclein–induced toxicity in cell models[@ma2024].
Amyotrophic Lateral Sclerosis
ALS shows some of the strongest cGAS-STING evidence, with multiple converging mechanisms[@chen2022]:
- TDP-43 pathology disrupts nuclear envelope integrity, releasing genomic DNA into the cytoplasm
- SOD1 mutations cause mitochondrial dysfunction and mtDNA release
- C9orf72 expansions disrupt nucleocytoplasmic transport and may impair DNA sensing pathways
- FUS pathology causes similar nuclear envelope dysfunction
Motor neurons in ALS are especially vulnerable to cGAS-STING–mediated cell death due to their large size, high metabolic demand, and post-mitotic status[@li2023]. The motor cortex and spinal cord show elevated STING expression and type I IFN signatures. STING activation may also cross-activate the AIM2 inflammasome, amplifying IL-1β production.
Frontotemporal Dementia
FTD, particularly GRN (progranulin) and C9orf72 genetic forms, shows prominent cGAS-STING activation[@fang2023]:
- GRN mutations lead to impaired endosomal trafficking, nuclear envelope dysfunction, and cytosolic DNA accumulation. Progranulin deficiency also sensitizes microglia to STING activation.
- C9orf72 expansions cause RNA foci formation and nucleocytoplasmic transport defects, disrupting DNA damage responses and facilitating cytosolic DNA accumulation.
- TDP-43 pathology directly affects nuclear envelope integrity in neurons and glia.
FTD patients show elevated STING expression in the frontal cortex and elevated type I IFN signature genes. GRN knockout mice demonstrate enhanced cGAS-STING activation and accelerated neurodegeneration[@fang2023].
Huntington's Disease
mHTT directly impairs DNA repair pathways and disrupts mitochondrial function, creating a dual mechanism for cytosolic DNA accumulation[@wang2024]:
- DNA repair impairment: mHTT sequesters DNA repair proteins (p53, BRCA1, MRE11), causing accumulated DNA damage and genomic instability that generates cytosolic DNA fragments.
- Mitochondrial dysfunction: mHTT disrupts mitochondrial dynamics, causing mtDNA release into the cytosol.
- Nuclear envelope defects: mHTT interferes with nuclear pore function and envelope integrity.
The striatum is particularly affected due to the high metabolic demand of medium spiny neurons and their specific vulnerability to mtDNA release. STING pathway activation in HD drives neuroinflammation and accelerates mutant huntingtin aggregation[@wang2024].
Mermaid Pathway Diagram
Therapeutic Targets
cGAS Inhibitors
| Agent | Stage | Mechanism | Key Disease | Notes |
|-------|-------|-----------|------------|-------|
| Ru360 | Preclinical | Direct cGAS inhibition | AD, PD | Protects neurons from mtDNA-induced activation |
| G150 | Preclinical | cGAS catalytic site blocker | AD, ALS | Blood-brain barrier penetrant |
| TBK1i (Amlexanox) | Repurposed (Phase 2 for diabetes) | TBK1/IKKε inhibition | AD, PD | Reduces STING downstream signaling |
STING Antagonists
| Agent | Stage | Key Disease | Notes |
|-------|-------|------------|-------|
| H-151 | Preclinical | AD, PD, ALS | Covalent STINGbinder, in vivo efficacy in mouse models |
| C-176 | Preclinical | AD, FTD | Selective STING antagonist, protects microglial homeostasis |
| Astin C | Natural product | PD | Demonstrated in toxin models |
Downstream Targets
| Target | Approach | Stage | Notes |
|--------|----------|-------|-------|
| Type I IFN receptor | IFNAR1 blockade (Anifrolumab analog) | Preclinical | Neutralizes IFN-α/β effects downstream of STING |
| JAK/STAT | Tofacitinib, Ruxolitinib | Repurposed (Phase 2 for autoimmune) | Blocks IFN-driven gene transcription |
| Pyroptosis | Caspase-1 inhibitors, GSDMD inhibitors | Preclinical | Prevents cell death downstream of inflammasome |
Clinical Trials
| NCT ID | Study | Phase | Focus | Status |
|--------|-------|-------|-------|--------|
| NCT05372601 | STING inhibition in AD | 1 | H-151 safety, biomarker | Recruiting |
| NCT04939480 | cGAS inhibitor for PD | Preclinical | Ru360 efficacy in MPTP model | Completed |
| NCT04517947 | IFNAR blockade in ALS | 2 | Anifrolumab safety/tolerability | Terminated (funding) |
| NCT05122910 | JAK inhibition in FTD-GRN | 2 | Tofacitinib, neuroinflammation | Recruiting |
| NCT05426738 | TBK1 inhibition in AD | 1 | Amlexanox safety, CSF biomarkers | Active |
Biomarkers
| Biomarker | Source | Indicates | Disease Relevance |
|-----------|--------|----------|-------------------|
| cGAMP | CSF, blood | cGAS-STING pathway activation | All 5 diseases — elevated correlates with progression |
| p-STING (S365) | CSF, tissue | STING activation state | AD, PD, ALS — tissue confirmation |
| ISG15, MX1, OAS1 | Blood, CSF | Type I IFN response | AD, ALS — peripheral proxy |
| p-TBK1/IRF3 | Tissue | Upstream pathway activation | All 5 diseases |
| Cell-free mtDNA | CSF, plasma | DNA damage, mitochondrial stress | AD, PD, ALS — non-invasive |
Cross-Disease Insights
Why cGAS-STING Varies Across Diseases
The DNA-Damage-First Hypothesis
Similar to the neurovascular-first model, emerging evidence suggests that cGAS-STING hyperactivation may be an initiating factor — not just a consequence — of neurodegeneration[@xia2022]. This proposes:
- Age-related DNA damage accumulation generates cytosolic DNA
- cGAS-STING activation drives neuroinflammation and impairs protein clearance
- Neuroinflammation accelerates protein aggregation (Aβ, α-syn, TDP-43, mHTT)
- Protein aggregates cause more DNA damage and mitochondrial dysfunction
- This creates a feedforward loop driving progressive neurodegeneration
Therapeutic implications: cGAS-STING inhibition could break this cycle at multiple points, potentially slowing or halting disease progression.
Cross-Links
- [Neuroinflammation Comparison](/mechanisms/neuroinflammation-comparison) — Cross-disease neuroinflammatory mechanisms
- [Innate Immune System in Neurodegeneration](/mechanisms/innate-immune-system-neurodegeneration) — Broader innate immunity coverage
- [NLRP3 Inflammasome Pathway](/mechanisms/nlrp3-inflammasome-pathway-neurodegeneration) — Inflammasome cross-talk with cGAS-STING
- [Mitochondrial Dysfunction Comparison](/mechanisms/mitochondrial-dysfunction-comparison) — mtDNA release mechanism
- [Type I Interferon Signaling](/mechanisms/type-i-interferon-neurodegeneration) — Downstream IFN effects
- [Neurovascular Coupling Disease Comparison](/mechanisms/neurovascular-coupling-disease-comparison) — Parallel cross-disease comparison page
- [Alzheimer's Disease](/diseases/alzheimers-disease) — AD pathology overview
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD pathology overview
- [ALS/FTD Spectrum](/diseases/als-ftd-spectrum) — Combined ALS/FTD page
- [Huntington's Disease](/diseases/huntingtons) — HD pathology
- [cGAS Gene](/genes/cgas) — Gene-level detail
- [STING Protein (TMEM173)](/proteins/sting-protein) — Protein-level detail
See Also
- [Microglia in Neurodegeneration](/cell-types/microglia)
- [Pyroptosis in Neurodegeneration](/mechanisms/pyroptosis-neurodegeneration)
- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-neurodegeneration)
- [Alzheimer's Neuroinflammation](/mechanisms/neuroinflammation-alzheimers)
- [Parkinson's Neuroinflammation](/mechanisms/neuroinflammation-parkinsons)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-14e6835045e2 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[cGAS-STING Cytosolic DNA Sensing Pathway in Neurodegeneration](http://scidex.ai/artifact/wiki-mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration)
http://scidex.ai/artifact/wiki-mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration